CSL Shares Plunge to 8-Year Low Amid CEO Departure and Weak Earnings

Australian biotech giant CSL saw its shares plummet to an 8-year low following the announcement of CEO Paul McKenzie's impending departure. This significant decline was further exacerbated by reports of the company's weak earnings performance. Investors are reacting negatively to the dual blow of leadership uncertainty and disappointing financial results. The plunge underscores a substantial bearish sentiment surrounding the company's near-term outlook. This development marks a challenging period for the prominent Australian pharmaceutical firm.